N-acetyl lysyltyrosylcysteine amide (KYC), an MPO-specific inhibitor, has been shown to effectively reduce oxidative stress-mediated brain injury after stroke by reducing 4-HNE and other toxic oxidants in vivo [68]. Here, MPO is linked to stroke disorder.